EKF Diagnostics Holdings PLC Trading update (8833A)
October 02 2020 - 2:00AM
UK Regulatory
TIDMEKF
RNS Number : 8833A
EKF Diagnostics Holdings PLC
02 October 2020
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) No 596/2014
(MAR)
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Trading update
Full year performance in-line with management expectations
October expected to be a record month for both PrimeStore MTM
and core business sales
PHE study: PrimeStore MTM only commercially available reagent
able to inactivate SARS-CoV-2
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed
point-of-care business, announces that trading in October is
expected to demonstrate continued and strong overall growth, and
that full year performance remains in-line with management
expectations, which have already been revised upwards several times
this year.
A significantly improved performance in the core business based
on October orders underpins the Board's confidence of an H2
recovery. This, combined with continued orders for the PrimeStore
MTM COVID-19 sample collection device, means that October is
expected to be a record month for EKF in terms of revenues and
profits.
The Company is also pleased to note that PrimeStore MTM was
successfully evaluated for effective SARS-CoV-2 inactivation in a
study published by Public Health England (PHE). The study showed
that of the few transport reagents, from the 23 tested, where no
residual virus was detectable, PrimeStore MTM is the only
commercially available CE-marked and FDA cleared transport media.
For more information visit:
https://www.ekfdiagnostics.com/primestore-mtm-evaluated-by-public-health-england-for-sars-cov-2.html
The PrimeStore MTM sample collection device deactivates viruses,
bacteria, fungi and mycobacterium tuberculosis allowing safe sample
handling and transport, greatly reducing risk of infection. The
device was invented in 2006 in preparation for a worldwide pandemic
and is designed to de-activate pathogen rapidly and stabilise the
RNA for up to four weeks with no requirement for cold storage. In
the case of COVID-19, by deactivating the virus testing can now
take place outside of containment facilities, opening up capacity
in more testing laboratories. With the flu season approaching, the
PrimeStore MTM can also safely collect flu and COVID-19 samples in
the same collection kit.
Due to the continued demand for PrimeStore MTM and the improving
performance of our core business the Board remains confident of
delivering on the strong full year performance reflected in
previously revised management expectations. Whilst it is too early
to make further revisions to these performance expectations,
trading in October is expected to suggest a strong Q4 performance.
The Company intends to provide a further update on trading in early
November.
The persons responsible for arranging the release of this
Announcement on behalf of the Company are Julian Baines, CEO, and
Richard Evans, FD and COO respectively.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0) 29 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0) 7980 541 893 / +44 (0) 7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analyzers in regular use
across more than 100 countries. EKF specializes in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analyzers.
About PrimeStore MTM
Global demand for the PrimeStore MTM sample containment device
has increased significantly due to COVID-19. The device was
invented in 2006 in preparation for a worldwide pandemic and is
designed to de-activate pathogen rapidly and stabilise the RNA for
up to four weeks with no requirement for cold storage. This
approach also allows samples to be tested by a greater number of
laboratories, as the handling risks for the deactivated virus are
reduced.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTVFLFBBBLBFBF
(END) Dow Jones Newswires
October 02, 2020 02:00 ET (06:00 GMT)
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2023 to Apr 2024